A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-28

Study Completion Date

2026-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB).

Researchers want to learn about MK-4646 when taken at the same time as Rifabutin.

They want to:

Measure a person's blood to find out if the amount of MK-4646 in the blood is the same when MK-4646 is taken alone or with Rifabutin Learn about the safety of MK-4646 when taken alone or with Rifabutin and if people tolerate it

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug Interaction Study

NCT00646776

Antivirals/HIV

COMPLETED PHASE1

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

NCT01138202

HIV Infections Tuberculosis

COMPLETED PHASE2

A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers

NCT03199690

HIV-1-infection Tuberculosis

UNKNOWN PHASE1

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin

NCT01700790

AIDS Tuberculosis

TERMINATED PHASE4

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470

HIV Tuberculosis

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MK-4646

On Period 1 Day 1, a single oral dose of MK-4646 will be administered.

Group Type EXPERIMENTAL

MK-4646

Intervention Type DRUG

Oral Capsule

MK-4646 with Rifabutin

Rifabutin will be administered orally once daily from Period 2 Day 1 through Period 2 Day 16. A single oral dose of MK-4646 will be administered on Period 2 Day 14.

Group Type EXPERIMENTAL

MK-4646

Intervention Type DRUG

Oral Capsule

Rifabutin

Intervention Type DRUG

Oral Capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK-4646

Oral Capsule

Intervention Type DRUG

Rifabutin

Oral Capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is in good health
* Has a body-mass index (BMI) between 18 and 32 kg/m2

Exclusion Criteria

* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* Has a history of cancer (malignancy)

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes